H-2 Antigens pp 705-716 | Cite as

The Role of Defective MHC Class I Expression for Tumor Growth and Metastasis

  • Günter J. Hämmerling
  • Daniela Klar
  • Uwe Maschek
  • Wolfgang Pülm
  • Knut Sturmhöfel
Part of the NATO ASI Series book series (NSSA, volume 144)

Abstract

The very early work on transplantation of murine tumors and “tumor rejection antigens” by pioneers such as Tyzzer, Little and Snell lead 50 years ago to the discovery of the major histocompatibility antigens. In the present overview it is discussed that MHC class I antigens induce not only the rejection of tumors in allogeneic hosts but that they are also fundamental for the rejection of tumors and metastasis in syngeneic hosts. The studies demonstrate that for induction of a specific T cell response the tumor cells have to express not only a novel tumor associated antigen but also MHC class I antigens. Numerous reports have demonstrated strong variations in the expression of class I antigens on mouse and rat tumors, e.g. on thymomas (Schmidt et al., 1979), on spontaneous lung carcinomas (Eisenbach et al., 1983), on methyl-cholantrene A induced fibrosarcomas (De Baetselier et al., 1980; Hämmerling et al., 1987), cells transformed with human adenovirus strain 12 (Bernards et al., 1983), etc.. On many human tumors variable expression of HLA antigens was also observed (see Table 4). Because cytotoxic T cells can recognize foreign antigens only in conjunction with MHC class I structures the decreased class I expression on tumors was interpreted to facilitate the escape from immune surveillance. However, all these assumptions were based on indirect evidence, namely on a correlation between the absence of class I antigens and the tumorigenic properties of the tumor cells.

Keywords

Tumor Rejection Antigen Mediate Lysis Major Histocompatibility Antigen Allogeneic Host Allele Specific Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alon, Y., Hämmerling, G.J., Segal, S. & Bar-Eli, M. (1987) Cancer Res., 47, 2553.PubMedGoogle Scholar
  2. Bernards, R., Schrier, P.I., Houweling, A., Bos, J.L. & van der Eb, A.J. (1983). Nature, 305, 776PubMedCrossRefGoogle Scholar
  3. Bernards, R., Dessain, S.K., Weinberg, R.A. (1986) Cell, 47, 667.PubMedCrossRefGoogle Scholar
  4. Bhan, A.K. & DesMarais, C.L. (1983). J. Nat. Canc. Inst., 71, 507.Google Scholar
  5. Daley, J.P., Wroblewski, J.M., Kaminsky, S.G. & Nakamura, I. (1987). Immunogenetics, 26, 21.PubMedCrossRefGoogle Scholar
  6. Dalianis, T., Ahrlund-Richter, L., Merino, F., Klein, E. & Klein, G. (1981). Immunogenetics, 12, 371.PubMedCrossRefGoogle Scholar
  7. De Baetselier, P., Katzav, S., Gorelik, E., Feldman, M. & Segal, S. (1980). Nature, 288, 179.PubMedCrossRefGoogle Scholar
  8. Doyle, A., Martin, W.J. & Funa, K. (1985). J. Exp. Med., 161, 1135.PubMedCrossRefGoogle Scholar
  9. Eisenbach, L., Segal, S. & Feldman, M. (1983). Int. J. Canc., 32, 113.CrossRefGoogle Scholar
  10. Ferguson, A., Moore, M. & Fox, H. (1985). Brit. J. Canc., 52, 551.CrossRefGoogle Scholar
  11. Harel-Bellan, A., Quillet, A., Marchiol, C., DeMars, R., Tursz, T. & Fradelizi, D. (1986). Proc. Nat. Acad. Sci., USA, 83, 5688.CrossRefGoogle Scholar
  12. Hämmerling, G.J., Klar, D., Moldenhauer, G., Momburg, F. & Pülm, W. (1986). Progress in Immunology VI, Eds. B. Cinader & R.A. Miller, Academic Press, p. 684.Google Scholar
  13. Hämmerling, G.J., Klar, D., Pülm, W., Momburg, F. & Moldenhauer, G. (1987). Biochimica et Biophysica Acta, Elsevier Science Publishers, Biomedical Division - Amsterdam, in press.Google Scholar
  14. Holden, C.A., Shaw, M., McKee, P.H., Sanderson, A.R. & MacDonald, D.M. (1984). Arch. Dermatol., 120, 732.PubMedCrossRefGoogle Scholar
  15. Hui, K., Grosveld, F. and Festenstein, H. (1984). Nature, 311, 750–752.PubMedCrossRefGoogle Scholar
  16. Johnson, P. W., Trumble, W. S., Hozumi, N. and Roder, J. C., (1987). J. Immunol., 138, 3996–4003.PubMedGoogle Scholar
  17. Kawano, Y.-I., Taniguchi, K., Toshitani, A. and Nomoto, K., (1986). J. Immunol., 136, 4729–4732.PubMedGoogle Scholar
  18. Kärre, K., Ljunggren, H. G., Piontek, G. and Kiessling, R., (1986). Nature, 119, 675.CrossRefGoogle Scholar
  19. Momburg, F., Degner, T., Bacchu, E., Moldenhauer, G., Hämmerling, G. J. & Möller, P., (1986a). Int. J. Canc., 37, 179.Google Scholar
  20. Möller, P., Herrmann, B., Moldenhauer, G. & Momburg, F., (1987). Int. J. Cancer, 40, 32.PubMedCrossRefGoogle Scholar
  21. Munro, S. & Pelham, H. R. B., (1986). Cell, 46, 291.PubMedCrossRefGoogle Scholar
  22. Ruiter, D. J., Bhan, A. K., Harrist, T. J., Sober, A. J. & Mihm, M. C., (1982). J. Immunol., 129, 2808.PubMedGoogle Scholar
  23. Schmidt, W., Altfield, G. & Festenstein, H., (1979). Immungenetics, 8, 311.CrossRefGoogle Scholar
  24. Tanaka, K., Isselbacher, K. J., Khoury, G. & Jay, G., (1985). Science, 228, 26.PubMedCrossRefGoogle Scholar
  25. Turbitt, M.L. & Mackie, R.M. (1981). Brit. J. Dermatol., 107, 507.Google Scholar
  26. Wallich, R., Bulbuc, N., Hämmerling, G.J., Katzav, S., Segal, S. & Feldman, M. (1985). Nature, 315, 301.PubMedCrossRefGoogle Scholar
  27. Whelan, J.P., Chatten, J. & Lampson, L.A. (1985). Canc. Res., 45, 5976.Google Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Günter J. Hämmerling
    • 1
  • Daniela Klar
    • 1
  • Uwe Maschek
    • 1
  • Wolfgang Pülm
    • 1
  • Knut Sturmhöfel
    • 1
  1. 1.Institute for Immunology and GeneticsGerman Cancer Research CenterHeidelbergW.-Germany

Personalised recommendations